CoreValve refutes alleged patent infringement action by Edwards Lifesciences: "We have great confidence in our technology and our legal right to
develop our ReValving(R) system for treatment of patients with
advanced aortic valve
IRVINE, Calif. (Business Wire EON/PRWEB ) February 15, 2008 --
CoreValve (www.corevalve.com) has
been informed that Edwards Lifesciences has filed a lawsuit in the
United States District Court in Delaware alleging infringement of
certain Edwards patents. CoreValve has reviewed the claims made by Edwards and believes the
lawsuit is without merit. CoreValve intends to vigorously defend its
intellectual property and its legal right to continue to develop and
clinically evaluate its proprietary ReValving®
System for percutaneous aortic valve replacement
in high-risk patients with advanced aortic valve disease. About CoreValve CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving®
System allows both percutaneous aortic valve replacement (PAVR)
and transapical aortic valve replacement (TAVR) and is intended
to provide an alternative to open-heart surgery. The ReValving®
System procedures are performed on the beating heart without cardiac
assistance or rapid pacing, and may result in less trauma to the
patient. This technology may also offer substantial cost-savings to the
healthcare system. The catheter-based technology includes a proprietary
framed/self-expanding tissue heart valve that is specifically designed
and engineered for transcatheter delivery. For more information about
CoreValve, visit the Company’s Web site at www.corevalve.com. (Caution: the CoreValve ReValving®
System will not be available in the USA for clinical trials or for sale
until further notice.)
| 
